Per­cep­tive's fourth — yes, fourth — SPAC jumps to Nas­daq as the blank check tree con­tin­ues to ripen

The biotech SPAC boom has gone al­most hand-in-hand with the in­dus­try’s IPO gold rush, and this week saw more blank check com­pa­nies hop aboard the train.

Lead­ing the way is Per­cep­tive Ad­vi­sors’ fourth SPAC, ap­pro­pri­ate­ly named Arya Sci­ences Ac­qui­si­tion IV, which priced Fri­day morn­ing af­ter rais­ing $130 mil­lion. And on top of that, new Zio­pharm ex­ec­u­tive chair James Huang is launch­ing his own SPAC with MSD Part­ners and Panacea Ven­ture, fil­ing S-1 pa­per­work Thurs­day with plans to raise $200 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.